Tien Liang BioTech Co's quarterly market cap
declined
from Jun. 2025 (NT$1,665.7 Mil) to Sep. 2025 (NT$1,599.3 Mil) and
declined
from Sep. 2025 (NT$1,599.3 Mil) to Dec. 2025 (NT$1,418.6 Mil).
Tien Liang BioTech Co's annual market cap
increased
from Dec. 2023 (NT$663.5 Mil) to Dec. 2024 (NT$1,899.0 Mil) but then
declined
from Dec. 2024 (NT$1,899.0 Mil) to Dec. 2025 (NT$1,418.6 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Tien Liang BioTech Co's Enterprise Value for Today is NT$3,956.0 Mil.
Tien Liang BioTech Co (ROCO:4127) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Tien Liang BioTech Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tien Liang BioTech Co Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Tien Liang BioTech Co's Market Cap distribution charts can be found below:
* The bar in red indicates where Tien Liang BioTech Co's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Tien Liang BioTech Co's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tien Liang BioTech Co (ROCO:4127) has a Market Cap of NT$3,509.8 Mil as of Jul. 07, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Tien Liang BioTech Co and its competitors. According to the industry distribution chart, Tien Liang BioTech Co ranks #604 out of 1024 companies in the Drug Manufacturers industry, placing it in the top 59%.
Is Tien Liang BioTech Co's Market Cap too high?
Tien Liang BioTech Co's current Market Cap is NT$3,509.8 Mil. Based on the distribution chart, Tien Liang BioTech Co ranks #604 out of 1024 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Tien Liang BioTech Co has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tien Liang BioTech Co's Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Tien Liang BioTech Co ranks #604 out of 1024 companies for Market Cap. This places Tien Liang BioTech Co in the lower half of its industry. The industry median Market Cap is 220.02. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 220.02, based on 1,024 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Tien Liang BioTech Co and its competitors. For the Drug Manufacturers industry, the median Market Cap is 220.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tien Liang BioTech Co's current Market Cap is NT$3,509.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tien Liang BioTech Co stock overvalued right now?
Based on GuruFocus' analysis, Tien Liang BioTech Co (ROCO:4127) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$39.18, compared to a current price of NT$76.70 — trading 95.8% above its estimated fair value. The current Market Cap is NT$3,509.8 Mil. Tien Liang BioTech Co's overall GF Score™ is 38/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Tien Liang BioTech Co (ROCO:4127), the current Market Cap is NT$3,509.8 Mil as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tien Liang BioTech Co (ROCO:4127) Overvalued in 2026?
Based on GuruFocus' analysis, Tien Liang BioTech Co stock appears to be overvalued.
The current stock price of NT$76.70 is trading 95.8% above its estimated GF Value™ of NT$39.18.
GuruFocus considers Tien Liang BioTech Co to be Significantly Overvalued.
Key valuation signals for ROCO:4127:
Market Cap: NT$3,509.8 Mil
GF Value™: NT$39.18 vs. price of NT$76.70 (95.8% above fair value)
No single metric tells the full story. See the ROCO:4127 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tien Liang BioTech Co Ltd develops and supplies chemicals, pharmaceutical, and Chinese herbs. It offers products for the treatment of intestinal track disease, osteoporosis, eye drops, cholesterin content, angiosclerosis, and hepatic diseases.
38GF Score
Get the complete analysis for ROCO:4127
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4127 has been successfully added to your 
